Gordon & Rees Austin partner Michael R. Klatt has been invited to speak on October 9 on an ABA conference panel on “Current Issues in Pharmaceutical and Medical Device Litigation.” The conference is sponsored by the Medical Device and Pharmaceutical Subcommittees of the American Bar Association Section of Litigation’s Products Liability Committee and will be held in Austin.
In the presentation, titled “Navigating Through Potential Landmines While Managing Litigation Concerning Live Products,” Klatt will discuss proposed amendments to Rule 26 and whether they will provide meaningful relief; the impact of the new U.S. Food and Drug Administration off-label publication distribution guidance and whether it will offer a safe harbor for manufacturers; and how the new FDA guidance addresses generics.
Klatt is a litigator in the Drug & Medical Device and Tort & Product Liability Practice Groups, handling class actions, mass torts, and individual product liability cases. A major focus of his practice is on the development of medical and scientific defenses to claims involving prescription and nonprescription pharmaceuticals, medical devices, and chemical exposures in both the mass tort and individual claim settings. His product liability experience also includes matters involving construction products, cosmetics, food contamination, veterinary products, and agricultural products including insecticides and pesticides.
Klatt frequently lectures at CLE events and University of Texas and Baylor University law schools regarding product liability and expert witness issues.
For more information about the workshop, click here.